Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Urinary Tract Calculi III: Medical Management

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease.

JAMA network open·2026

Same author

Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.

AACE endocrinology and diabetes·2026

Same author

Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention-Diuretic Comparison Project.

Journal of the American Heart Association·2026

Same author

Social Determinants of Health ICD-10 Code Use by a Large Integrated Healthcare System.

Healthcare (Basel, Switzerland)·2025

Same author

Home Blood Pressure Monitoring in Routine Care-Factors Associated with Enrollment and Blood Pressures Recorded in the Veterans Health Administration.

American journal of hypertension·2025

Same author

Medication Adherence in the Real World: Lessons from the Diuretic Comparison Project.

Journal of clinical medicine·2025

Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026

Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026

Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026

Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026

Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026

Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

WITHDRAWN: Cernilton for benign prostatic hyperplasia.

Timothy J Wilt¹, Roderick Macdonald, Areef Ishani

¹General Internal Medicine (111-0), VAMC, One Veterans Drive, Minneapolis, Minnesota, USA, 55417.

The Cochrane Database of Systematic Reviews

|May 13, 2011

Summary

This summary is machine-generated.

Cernilton, derived from rye-grass pollen, modestly improves self-rated urinary symptoms and nocturia in men with benign prostatic hyperplasia (BPH). However, it did not show significant effects on urinary flow or prostate size, with rare adverse events reported.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Related Experiment Videos

Last Updated: Jun 2, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Area of Science:

Phytotherapy
Urology
Pharmacology

Background:

Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
Phytotherapy, using plant-based remedies, is increasingly explored for BPH management.
Cernilton, a rye-grass pollen extract, is one such phytotherapeutic agent.

Purpose of the Study:

To systematically review the efficacy of Cernilton in treating urinary symptoms and improving flow measures in men with BPH.
To assess the impact of Cernilton on subjective and objective outcomes related to BPH.

Main Methods:

Systematic review of randomized controlled trials (RCTs) and controlled clinical trials.
Searched multiple databases (MEDLINE, EMBASE, Cochrane Library, Phytodok) and contacted manufacturers.
Included trials comparing Cernilton with placebo or other BPH medications, assessing urologic symptom scales and urodynamic measurements.

Main Results:

Cernilton improved self-rated urinary symptoms compared to placebo and Tadenan (RR 2.40 vs placebo, RR 1.42 vs Tadenan).
Nocturia was reduced with Cernilton versus placebo (RR 2.05) and Paraprost (WMD -0.40).
No significant improvements were observed in urinary flow rates, residual volume, or prostate size. Adverse events were rare and mild.

Conclusions:

Available evidence suggests Cernilton is well-tolerated and offers modest improvements in overall urologic symptoms, including nocturia.
Limitations include short trial durations, small sample sizes, and unclear preparation quality.
Further high-quality, long-term randomized controlled trials are necessary to confirm clinical effectiveness and safety.